Pvg指出,他们认为Anavex Life Sciences Corp.难以凭借现有团队获取推动Blarcamesine 2B/3期临床试验所需的资金支持。这一判断直指公司当前面临的融资困境。
Pvg指出,他们认为Anavex Life Sciences Corp.难以凭借现有团队获取推动Blarcamesine 2B/3期临床试验所需的资金支持。这一判断直指公司当前面临的融资困境。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.